References
- Silvestri E, Emmi G, Prisco D. Vascular Behçet disease: new insights in the management of thrombosis. Expert Rev Cardiovasc Ther 2013;11(12):1583-5
- Emmi L, Prisco D. Behçet’s Syndrome: from Pathogenesis to Treatment, Series – Rare Diseases of the Immune System. Springer; 2014
- Davatchi F, Assaad-Khalil S, Calamia KT, et al. The international criteria for behçet’s disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2014;28(3):338-47
- La Regina M, Gasparyan AY, Orlandini F, Prisco D. Behçet’s disease as a model of venous thrombosis. Open Cardiovasc Med J 2010;4:71-7
- Balta I, Balta S, Koryurek OM, et al. Serum endocan levels as a marker of disease activity in patients with Behçet’s disease. J Am Acad Dermatol 2014;70(2):291-6
- Balta I, Balta S, Koryurek OM, et al. Mean platelet volume is associated with aortic arterial stiffness in patients with Behçet’s disease without significant cardiovascular involvement. J Eur Acad Dermatol Venereol 2013. [Epub ahead of print]
- Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behçet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum 2011;41(1):61-70
- Adler S, Baumgartner I, Villiger PM. Behçet’s disease: successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis. Arthritis Care Res (Hoboken) 2012;64(4):607-11
- Perra D, Alba MA, Callejas JL, et al. Adalimumab for the treatment of Behçet’s disease: experience in 19 patients. Rheumatology (Oxford) 2012;51:1825-31
- Olivieri I, Leccese P, Padula A, et al. High prevalence of Behçet’s disease in southern Italy. Clin Exp Rheumatol 2013;31:28-31
- Emmi G, Silvestri E, Squatrito D, et al. Behçet’s syndrome pathophysiology and potential therapeutic targets. Intern Emerg Med 2014. [Epub ahead of print]
- Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008;67:1656-62